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ABSTRACT
Carbonic anhydrase IX (CAIX) is a hypoxia-related protein considered as a predictor for oral squamous cell
carcinoma (OSCC) biological behaviour. Nevertheless, this prognostic value is still yet to be validated. We
aim to quantify prognostic significance of CAIX overexpression in OSCC by meta-analysis. We performed
searches in MEDLINE, EMBASE, SCOPUS, WOS, WHO’S databases, CPCI, and OATD from inception to
August 2019. Overall survival (OS), disease-free survival (DFS), locoregional control (LC), and disease-spe-
cific survival (DSS) were considered as outcomes of interest. Overall 18 studies were included. CAIX over-
expression was associated with worse OS (hazard ratio [HR]¼ 1.45 95% confidence interval [CI] 1.17–1.80)
and DFS (HR ¼ 1.98 95% CI 1.18–3.32). To the contrary, it was neither associated with LC (HR ¼ 1.01
95% CI 0.50–2.02) nor with DSS (HR ¼ 1.35 95% CI 0.78–2.33). Heterogeneity was negligible in all analyses
except for DSS. Small studies effect was not significant for OS and DFS. This study shows that immunohis-
tochemical CAIX assessment is a useful OSCC prognostic biomarker.
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Hypoxia is one of the most complex conditions that cellular and
extracellular matrix confront in order to preserve their homeosta-
sis1. Bearing the hallmarks of cancer in mind as described by
Hanahan and Weinberg, hypoxic metabolic reprogramming elicits
complex mechanisms which take place in the microenvironment
of many solid tumours2,3. Two of the key transcription factors that
play major roles in this metabolic reprogramming are the hypoxia
inducible factors (HIFs), namely HIF-1a and HIF-2a4. Carbonic anhy-
drase IX (CAIX) is a HIF-1a-dependent protein that regulates cellu-
lar and extracellular pH homeostasis under hypoxia, playing a
pivotal role in carcinogenesis and in the malignant transition of
premalignant disorders5–7. Several studies have evaluated the
prognostic value of CAIX in different types of cancer, including
oral squamous cell carcinoma (OSCC)8,9.
OSCC accounts for 95% of all oral malignant neoplasms and its
global five-year survival rate ranges between 50 and 60%10. The
TNM cancer staging system is still considered to be of great prog-
nostic value for this solid tumour11. Nonetheless, this system can-
not be used to accurately predict the biologic properties of OSSC,
nor can it be used to provide guidance for treatment strategies
from a molecular biology perspective. Analysing molecular altera-
tions in order to detect specific abnormalities at a transcriptional,
translational, and post-translational level has proven to be of par-
ticular interest12,13. In this line, immunohistochemistry (IHC) – the
use of mono and polyclonal antibodies to determine the tissue
distribution of an antigen – has an outstanding oncological
impact14. Nonetheless, the clinical translation of these IHC-based
approaches in terms of decision-making, remains suboptimal for
many solid tumours14,15.
There is growing evidence which confirms the key role of CAIX
in oral oncogenesis. Numerous publications have explored a pos-
sible relationship between CAIX expression and OSCC prognosis,
as well as the rate of progression from oral potentially malignant
disorders to OSCC16–18.
The only meta-analysis carried out on this issue so far did not
assess the prognostic value in subgroups19. It is known that the
prognosis of head and neck cancers is different through tumour
locations. It is then of paramount importance to carry out sub-
group analyses20.
We, therefore, decided to perform a systematic review and
meta-analysis on the influence of CAIX expression on the long-
term outcomes of patients suffering from OSCC.
2. Material and methods
2.1. Protocol and eligibility criteria
A systematic literature review was conducted in November 2019
and the protocol used adhered to the PRISMA guidelines21. The
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search question was formulated according to the PECO frame-
work, and it read as follows: What is the prognostic value of
tumoural CAIX immunohistochemical expression in patients
with OSCC?
2.2. Sources
Electronic searches were carried out in MEDLINE via PubMed,
EMBASE via OVID, Web of Science, Scopus, the WHO five
regional bibliographic databases (AIM, LILACS, IMEMR, IMSEAR,
and WPRIM), and the Conference Proceedings Citation Index
databases. For Medline, the following algorithm was used both
in the Medical Subject Heading and in the free text words:
(“CAIX”) OR (“ca9”) OR (“carbonic anhydrase IX”) OR (“carbonic
anhydrase 9”) OR (“carbonic anhydrase-IX”) OR (“carbonic anhy-
drase-9”) OR (“CA-IX”) OR (“ca-9”) OR (“G250”) AND (“carcinoma,
squamous cell” OR “carcinoma” AND “squamous” AND (“cell”)
OR “squamous cell carcinoma”) OR (“mouth neoplasm”). The
aforementioned syntax was conveniently adapted for each data-
base. All of the databases were searched from inception to
August 2019. This process was complemented by a manual
search in a series of peer-reviewed journals with related con-
tent. Potentially relevant articles that any of the authors were
familiar with, as well as reference lists from the retrieved
articles, were also comprehensively checked. In these searches,
no language restrictions were applied.
2.3. Study selection and data extraction process
The study eligibility criteria were applied independently by two
trained reviewers (A.I.L.P. and M.P.S.). Any discrepancies were
resolved by consensus of all participating authors.
Criteria for eligibility for retrieved studies in the qualitative/
quantitative analysis were as follows: i) original research articles
published in any language; ii) assessing CAIX expression in biop-
sies from patients with OSCC using IHC methods; iii) analysing the
association between CAIX overexpression with any of the follow-
ing long-term outcomes: overall survival (OS), disease-free survival
(DFS), locoregional control (LC), and disease-specific Survival (DSS).
The exclusion criteria were as follows: i) case reports, editorials, or
letters; in vitro or animal-based studies; ii) insufficient statistical
data to estimate predefined outcomes; iii) studies evaluating CAIX
protein-related genes or miRNAs; iv) studies with dupli-
cated cohorts.
In the first round, the title and abstract of the retrieved
articles and studies which met the inclusion criteria were read
and any texts which presented insufficient data in order for a
clear decision to be made were assessed following a full-text
protocol. Subsequently all of the studies which were considered
eligible were fully examined in a second round and the final
decision as to whether or not they were to be included was
made. This form included the following items: first author, year
of publication, country and continent where the study was con-
ducted, sample size, recruitment period, tumour subsite, treat-
ment modality, follow-up period, cut-off value for CAIX
IHC positivity, immunostaining pattern (nuclear/cytoplasmic),
hazard ratios (HRs) for long-term outcomes, and adjust-
ment variables.
2.4. Quality assessment, data synthesis, and analysis
Quality was independently assessed by two authors (O.A.C. and
C.M.C.P.) by means of a variation of the criteria formulated in the
Reporting Recommendations for Tumour Marker Prognostic
Studies (REMARK) guidelines for prognostic studies and the
Standards for Reporting of Diagnostic Accuracy (STARD) devel-
oped by Troiano et al22. This variation included six dimensions
which evaluated:
1. Samples: i) Cohort (retrospective or prospective) study with a
well-defined study population; ii) Medical treatment applied
to the patients was explained. Authors have explained if all
patients have received the same treatment or not.
2. Clinical data of the cohort: The basic clinical data such as
age, gender, clinical stage, and histopathological grade
was provided.
3. IHC: Well-described staining protocol or referred to ori-
ginal paper.
4. Prognosis: The analysed survival endpoints were well defined
(e.g. OS and DFS).
5. Statistics: i) Cut-off point, which is used to divide the cases
into risk groups was well described; ii) Estimated effect
describing the relationship between the evaluated biomarker
and the outcome was provided; (iii) Adequate statistical ana-
lysis (e.g. Cox regression modelling) was performed to adjust
the estimation of the effect of the biomarker for known prog-
nostic factors.
6. Classical prognostic factor: The prognostic value of other clas-
sical prognostic factors and its relationship with the studied
factor was reported.
Each parameter could be identified by one of three attributes
(i.e. adequate [A], inadequate [I], or non-evaluable [N/A]. Each
item scored as adequate adds one point to overall quality assess-
ment for each study. A score sheet was prepared for each
included study and quality scoring was independently undertaken
by aforementioned author. In the event of disagreement, the
scores were discussed until a consensus was reached. Studies
were categorised as high quality when the overall score was >4.
The differences in the levels of CAIX staining were categorised
as high and low, according to the cut-off value which was chosen
by the authors of the studies. HRs and 95% confidence intervals
(CIs) were used as the measure of association in order to estimate
the impact of CAIX expression on the aforementioned long-term
outcomes (OS, DFS, LC, and DSS). Multivariate or univariate HRs
values were used but, when available, the formers were chosen.
When data on the HRs could not be directly traced, these were
calculated using the approximation methods described by Parmar
et al.23 and Tierney et al.24. Lastly, when access was provided to
full databases, the HRs were directly extracted.
Pooled analyses were obtained using both fixed-effect models
(i.e. Mantel–Haenszel method) and random-effect models
(i.e. DerSimonian and Laird method), but when substantial
heterogeneity was detected, we based our assessment only on
random-effects models. A subgroup analysis on the basis of sev-
eral variables was planned (i.e. quality score, ethnic variations,
tumour subsite, CAIX antibody, cut-off point, and type of covariate
adjustment). The heterogeneity was assessed using the proportion
of the total variance due to the variance between studies (Ri)
25.
Large values (>0.75) indicate a large amount of heterogeneity,
values between 0.4 and 0.75 suggest a moderate amount,
whereas small values (<0.4) indicate a low amount of
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heterogeneity. Funnel plots were used to visually assess publica-
tion bias and the Egger’s test was used in order to conduct a
more formal analysis. Stata version 14.1 (Stata Corp, College
Station, TX, US) and HEpiMA version 2.1.3 (Corunna, Galicia, Spain)
were employed26.
3. Results
3.1. Characteristics of the included studies
Out of the 1741 publications which were initially retrieved, 18
studies met our inclusion criteria and were included in the meta--
analysis, as depicted in Figure 1. The studies reported on a total
of 1616 OSCC-affected patients27–44.
The data was collected in a period spanning from 1987 to
201527–44 while the year of publication ranged from 2008 to 2019.
The anatomic location of the tumours was mainly divided into
exclusively tongue27,28,30,31,37,39,42, or mixed subsite tumours
29,32–36,38,40,41. The population sample ranged from 21 in Roh et al.
study30 to 271 in Yang et al. study38. The studies were carried out
in Asia, Europe, and America. Half of the studies were carried out
in Asia (specifically in China38, Japan27,33, and South
Korea28–30,32,35,37) and the other half in Brazil39,43, Canada34,
Germany31,44, Portugal40, Spain36,40,42, and the US41. The retrieved
data are summarised in Table 1. The individual HRs for each
selected long-term outcome with its respective adjustment is
reflected in Table 2. The authors had full access to three full data-
bases36,40,42. An article-based doctoral dissertation retrieved via
LILACS needed to be fully assessed for its HR estimation39.
3.2. Quality assessment and pooled analysis of the
included studies
The quality assessment which was performed in accordance with
the REMARK guidelines is summarised in Table 3. According to
these criteria ten studies showed a good quality, although eight
were considered at high risk of bias. Table 4 lists the pooled effect
estimates for all 18 studies, for each of the selected long-term
outcomes, as well as the analysis of its subgroups. A fixed-effects
model was used to evaluate the pooled HR with 95% CI for the
outcomes of OS, DFS, and LC, given that they displayed low het-
erogeneity. A random-effects model was used for DSS due to its
high heterogeneity. A higher CAIX expression is associated with a
Figure 1. Flowchart for inclusion of the studies according to the PRISMA guidelines.
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statistically significant worse OS (HR ¼ 1.45, 95% CI 1.17–1.80),
and in the case of DFS, the pooled analysis reflected almost a
two-fold increase in the hazard for this outcome (HR ¼ 1.98,
95% CI 1.18–3.32). However, higher CAIX expression is apparently
not related to LC (HR ¼ 1.01, 95% CI 0.50–2.02), nor to DSS (HR ¼
1.35, 95% CI 0.78–2.33).
The funnel plot for OS (Figure 3) indicates a minimal skewness
to the right that was not confirmed by the Egger’s test (PEgger ¼
0.59). In the case of DFS, this statistical test also indicates the
absence of publication bias (PEgger ¼ 0.29).
In the OS subgroup analysis, the statistically significant associ-
ation was not preserved in the non-Asian (HR ¼ 1.19, 95% CI
0.91–1.57), low quality (HR ¼ 1.21, 95% CI 0.64–2.29), and tongue
carcinoma subgroups (HR ¼ 1.18, 95% CI 0.84–1.66). The analysis
showed that the pooled HR was twice higher for the Asian group
(HR ¼ 2.01, 95% CI 1.42–2.86) when compared to the Non-Asian
group. Furthermore, the use of M75 antibody and the choice of a
10% cut-off point were related with increased HR, [HR ¼ 1.93,
95% CI 1.29–2.88], and HR ¼1.72, 95% CI 1.14–2.59), respectively.
In the case of DFS, its statistical significance was preserved in the
Asian group (HR ¼ 1.81, 95% CI 1.06–3.09), mixed subsites (HR ¼
3.24, 95% CI 1.35–7.76), and use of other cut-off points than 10%
for IHC subgroups (HR ¼ 2.50 95% CI 0.91–6.89) (Figure 2).
4. Discussion
Globally, this systematic review and meta-analysis show that CAIX
overexpression is correlated with worse OS and DFS in OSCC
patients, indicating that positivity for this test implies that the
overall risk of dying increases by about 50%. The relation between
CAIX expression and OS and DFS appears to confirm the prognos-
tic value that is attributed to this marker on the basis of its rela-
tion with the HIF pathway9,45. CAIX contributes to the tumour
microenvironment by maintaining extracellular acidic pH and
helping cancer cells grow and metastasise in several other
solid tumours5,6.
Our study showed a lower prognostic value for OS and DFS
than that shown in Peridis et al.’s study19. Our study may be more
reliable due to the accumulation of studies with high-quality
scores and lower heterogeneity across studies. In addition, to our
knowledge, our study is the first meta-analysis to measure this
prognostic value exclusively in OSCC.
The relative consistency of the results across subgroups rein-
forces the plausibility of the findings. First, publication bias is a
highly unlikely explanation for the present results given the find-
ings of the asymmetry tests of the funnel plot for both OS and
DFS (Figure 3). It is worth mentioning that we observed that a
relevant part of the studies included in our meta-analysis did
not provide HRs estimates adjusted for relevant cofounders,
although subgroup analysis demonstrated that even after the
use of fully adjusted models for multiple established OSCC risk
factors the OS remained with the same magnitude. Also, the
hypoxic nature of these tumours is highly influenced by the
crosstalk with other molecular pathways such cell cycle or angio-
genesis, and in our review several reports took these factors
into account9.
Second, the heterogeneity of the studies included in the pre-
sent meta-analysis was generally small especially in relation to LC,
DFS, and OS (Table 4). On the contrary, there was high heterogen-
eity in DSS. We relate this finding to the fact that survival parame-
ters were undefined in some studies, largely due to the lack of
international consensus on the definitions of long-term outcomes.
In the OS subgroup analysis, CAIX overexpression also had a par-
ticularly negative impact on the OS of Asian patients. These differ-
ences could be linked to genetic and lifestyle variabilities10. This
study also identified that variations at the level of staining proto-
col also resulted in significant variations in survival endpoints. In
the case of the DFS subgroup analysis, a stronger association in
the OSCC mixed subsites subgroup, when compared exclusively
with the tongue carcinoma subgroup, was observed. Prognostic
OSCC studies have classically described tongue carcinomas as
those tumours which carry the worst prognosis due to the lymph-
atic richness and the more pronounced diagnostic delay9–12. We
relate this finding to the possible existence of residual confound-
ing given that some studies pooled data regarding unspecified
oral cancer subsites.
This study dealt with the IHC-based CAIX expression in OSCC
tissue as a prognostic but not a predictive biomarker.
Nonetheless, recent studies have shed light on its promising value
as a predictor of the malignant transformation of some orally
potentially malignant disorders, such as oral leukoplakia16. CAIX as
a target is of particular interest in oncology as there are a number
of CAIX inhibitors available7. The interference of the HIF pathway
with these inhibitors in OSCC has been poorly explored, nonethe-
less, according to the recent studies carried out by our group, sev-
eral CAIX inhibitors which were synthesised on phenolic bis
mannich bases and sulphonamides showed promising in vitro
cytotoxicities in several OSCC cell lines46–49.
Figure 2. Forest plot for the association of higher CAIX expression with overall
survival (A), disease-free survival (B).
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The results from this systematic review and meta-analysis are
supported by strong evidence. However, when interpreting the
main results from this meta-analysis, some of the limitations of
the individual studies cannot be ignored. Some authors recorded
ambiguity in the distinction between OS and DSS. In addition,
some authors did not directly report HR values in the survival
analysis and this had to be approximated. In addition, adjust-
ment for multiple established OSCC risk factors varied widely in
the included studies. Despite this, we believe that these results
are reliable and more widely applicable. However, further immu-
nohistochemical reports are needed in order to validate
this biomarker.
Table 3. Quality score according to the REMARK guidelines.
Study Year Samples Clinical data of the cohort
Immunohisto
chemistry Prognosis Statistics Classical prognostic factors Overall risk of bias
Sakata K et al. [27] 2008 A I A I I I 2
Kim SJ et al. [28] 2007 A A A A A A 6
Choi SW et al. [29] 2008 A A A I A A 5
Roh JL et al. [30] 2009 A A A A A A 6
Eckert AW et al. [31] 2010 A A A N/A I I 3
Han MW et al. [32] 2011 A I A I A A 4
Kondo Y et al. [33] 2011 A A A A A A 6
Brockton NT et al. [34] 2012 A I A A A A 5
Heo K et al. [35] 2012 I A A I A A 4
Perez-Sayans M et al. [36] 2012 A A A I A A 5
Hwa JS et al. [37] 2015 I A A I I I 2
Yang JS et al. [38] 2015 I A A I A A 4
Vasconcelos MG et al. [39] 2015 A I A I I A 3
Simoes-Sousa S et al. [40] 2016 I A A A A A 5
Brockton NT et al. [41] 2017 A A A A A A 6
Saenz-de-Santa-Marıa I et al. [42] 2017 A I A A A I 4
Peterle GT et al. [43] 2018 A A A I A A 5
Eckert AW et al. [44] 2019 A A A A A A 6
Items were assessed as A: Adequate; I: Inadequate; N/A: no description.
Table 2. Synthesis of data extracted from the included studies related to outcomes pooled in the meta-analysis.
Study OS (HR 95% CI) DFS (HR 95% CI) LC (HR 95% CI) DSS (HR 95% CI) Adjustment
Sakata K et al. [27] NR NR 0.91 (0.32–2.61) NR Multivariate adjusted for
T stage and
microvessel density.
Kim SJ et al. [28] 2.99 (1.39–6.45) 1.76 (0.89–3.51) NR NR None
Choi SW et al. [29] 1.91 (0.77–4.71) 1.77 (0.56–5.56) NR NR None
Roh JL et al. [30] NR NR 1.09 (0.43–2.76) 0.71 (0.23–2.22) None
Eckert et al. [31] 1.34 (0.65–2.76) NR NR NR Multivariate adjusted for
tumour size and
tumour grade.
Han MW et al. [32] 0.65 (0.12–3.67) 0.80 (0.50–3.15) NR NR Multivariate adjusted for
tumour size and
tumour grade.
Kondo Y et al. [33] 3.36 (0.97–11.70) NR NR NR None
Brockton NT et al. [34] NR NR NR 2.96 (1.01–8.66) Multivariate adjusted for
tumour stage and
nodal involvement.
Heo K et al. [35] NR 6.82 (1.22–37.94) NR NR None
Perez-Sayans M
et al. [36]
1.36 (0.43–4.26) NR NR 2.04 (0.76–5.49) None
Hwa JS et al. [37] NR NR NR 0.29 (0.05–1.77) None
Yang JS et al. [38] 1.76 (1.07–2.87) NR NR NR None
Vasconcelos MG
et al. [39]
0.86 (0.23–3.26) NR NR NR None
Simoes-Sousa S
et al. [40]
0.76 (0.44–1.38) NR NR NR None





1.14 (0.69–1.89) NR NR NR Multivariate adjusted for
tumour stage and
nodal involvement.
Peterle GT et al. [43] NR 8.75 (0.99–77.19) NR 2.84 (1.02–7.87) Multivariate adjusted for
tumour size and the
use of Rx.
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5. Conclusions
In view of the results obtained, we believe that IHC assessment of
CAIX expression may be useful as a prognostic biomarker for
OSCC, especially in the case of OS and DFS. These results open up
the possibility of using this hypoxia-related protein in the progno-
sis of OSCC, and in its prevention and early control. Future studies
with larger sample sizes and well-designed inclusion criteria are
warranted in order to assess the role of CAIX IHC-based expression
in determining the prognosis of OSCC.
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Table 4. Pooled hazard ratios and 95% confidence intervals.
Number of studies Pooled HR (95% CI), fixed effects Pooled HR (95% CI), random effects Ri

Q test p Value
Overall survival
Overall 11 1.45 (1.17–1.80) 1.46 (1.12–1.89) 0.26 .21
High quality 6 1.48 (1.18–1.86) 1.51 (1.11–2.06) 0.38 .13
Low quality 5 1.21 (0.64–2.29) 1.21 (0.64–2.29) 0.00 .57
Full adjustment 4 1.48 (1.18–1.86) 1.51 (1.11–2.06) 0.38 .13
Asian 5 2.01 (1.42–2.86) 2.01 ( 1.42–2.86) 0.00 .45
Non-Asian 6 1.19 (0.91–1.57) 1.19 (0.91–1.57) 0.00 .45
Tongue 4 1.18 (0.84–1.66) 1.22 (0.66–2.27) 0.66 .04
Mixed subsites 7 1.48 (1.14–1.91) 1.48 (1.10–2.00) 0.22 .29
Use of M75 antibody 3 1.93 (1.29–2.88) 1.93 (1.29–2.88) 0.00 .39
Use of other antibodies 8 1.29 (1.00–1.67) 1.29 (0.96–1.75) 0.21 .27
Use of 10% cut-off point 6 1.72 (1.14–2.59) 1.69 (1.06–2.69) 0.17 .31
Use of other cut-off points 5 1.36 (1.06–1.75) 1.36 (0.98–1.88) 0.39 .17
Disease-free survival
Overall 5 1.98 (1.18–3.32) 2.12 (1.02–4.43) 0.40 .19
Asian 4 1.81 (1.06–3.09) 1.82 (0.90–3.69) 0.34 .25
Tongue 2 1.51 (0.79–2.88) 1.27 (0.43–3.74) 0.57 .21
Mixed subsites 3 3.24 (1.35–7.76) 3.58 (1.26–10.12) 0.26 .39
Use of 10% cut-off point 3 1.82 (0.99–3.33) 1.85 (0.59–5.77) 0.65 .12
Use of other cut-off points 2 2.50 (0.91–6.89) 2.98 (0.69–12.91) 0.48 .20
Locoregional control
Overall 2 1.01 (0.50–2.02) 1.01 (0.50–2.02) 0.00 .80
Disease specific survival
Overall 6 1.00 (0.99–1.01) 1.35 (0.78–2.33) 1.00 .03
Asian 2 0.55 (0.21–1.44) 0.55 (0.21–1.44) 0.00 .41
Non-Asian 4 1.00 (0.99–1.01) 1.79 ( 0.90–3.54) 1.00 .01
Tongue 2 0.55 (0.21–1.44) 0.55 (0.21–1.44) 0.00 .41
Mixed subsites 4 1.00 (0.99–1.01) 1.79 (0.90–3.54) 1.00 .02
Ri stands for the proportion of the total variance due to between studies variance.
Figure 3. Funnel plot of publication bias for higher CAIX expression and over-
all survival.
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